

Listing Notice

November 19, 2013

Listing of 8,113,845 registered shares
and formal listing of 3,151,607 registered shares
at the SIX Swiss Exchange (Main Standard)

<p>Issuer</p>	<p>Cytos Biotechnology Ltd., Schlieren, a stock corporation organized under Swiss law (the "Issuer" or the "Company").</p> <p>Registered office and address: Wagistrasse 25, 8952 Schlieren, Switzerland.</p>
<p>Securities to be listed</p>	<p>(i) Listing of 6,303,215 registered shares of the Issuer with a nominal value of CHF 0.10 each, in connection with an ordinary capital increase (the "Capital Increase Shares"),</p> <p>(ii) Listing of 1,810,630 registered shares of the Issuer with a nominal value of CHF 0.10 each, issued out of authorized share capital (the "Authorized Shares"), and</p> <p>(iii) formal listing of 3,151,607 registered shares of the Issuer with a nominal value of CHF 0.10 each, in connection with a conditional capital increase, (the "Conditional Shares"; together with the Capital Increase Shares and the Authorized Shares, the "New Shares").</p> <p>The New Shares are registered shares (<i>Namenaktien</i>). The New Shares are issued in uncertificated form (<i>Wertrechte</i>) and entered in the Company's book of book-entry securities (<i>Wertrechtbuch</i>). The Shares will then be registered in the main register (<i>Hauptregister</i>) maintained by SIS and credited to the securities account of each holder of Shares and thus will become intermediary-held securities (<i>Bucheffekten</i>). However, a shareholder may at any time request the Company to issue a confirmation of such shareholder's shareholding.</p>
<p>Listing / First Day of Trading</p>	<p>The listing of the Capital Increase Shares and the Authorized Shares and the formal listing of the Conditional Shares has been requested and approved for the Main Standard of the SIX Swiss Exchange.</p> <p>The planned listing date of the New Shares and first day of trading is November 20, 2013.</p>

<p>Summary information on the conditions attached to the New Shares</p>	<p>The New Shares are fully fungible and rank <i>pari passu</i> with each other and with all other issued shares of the Issuer, including with respect to dividends, to a share in the liquidation proceeds in case of a liquidation of the Company and to subscription rights (<i>Bezugsrecht</i>).</p> <p>The New Shares are subject to the transfer restrictions of Art. 5 of the Issuer's articles of association (<i>vinkulierte Namenaktien</i>).</p>
<p>Security Number / ISIN / Common Code / Symbol</p>	<p>Swiss Security Number (<i>Valorenummer</i>): 1 102 521</p> <p>ISIN: CH 001 102 521 7</p> <p>Common Code: 015626003</p> <p>Trading symbol: CYTN</p>
<p>Listing Prospectus</p>	<p>Hardcopies of the listing prospectus dated November 5, 2013 with the supplement dated November 18, 2013 (the "Listing Prospectus") are available free of charge in Switzerland at Cytos Biotechnology Ltd., Wagistrasse 25, 8952 Schlieren, by telephone (number +41 44 733 47 47) during regular business hours, facsimile (number +41 733 47 40) or e-mail (harry.welten@cytos.com).</p> <p>The Listing Prospectus is the only authoritative source of information on the listing of the Capital Increase Shares and the Authorized Shares and the formal listing of the Conditional Shares at the SIX Swiss Exchange.</p>
<p>Indication of any factors that depart significantly from normal market practice, as well as any other important provisions which are given a prominent place in the Listing Prospectus</p>	<p>The Issuer has not been registered under the US Investment Company Act of 1940, as amended, and does not intend to do so. The New Shares have not been and will not be registered under the United States Securities Act of 1933, as amended, or with any securities regulators of any state or other jurisdiction of the United States, and may not be offered, sold or delivered within the United States or to United States Persons absent registration or under an applicable exemption from the registration requirements of such securities laws.</p> <p>Any person in a Member State of the EEA who acquires New Shares, will be deemed to have represented and agreed that they are "Qualified Investors" within the meaning of Art. 2(1)(e) of the Prospectus Directive 2003/71/EC, as amended, and that the New Shares have not been acquired on behalf of, nor with a view to their offer or resale to, persons in any Member State of the EEA other than Qualified Investors.</p> <p>The Issuer assumes responsibility for the completeness and accuracy of this Listing Prospectus pursuant to Section 4 of Scheme A of Annex I to the SIX Listing Rules.</p>

	<p>The Listing Prospectus may contain forward-looking statements.</p> <p>The Listing Prospectus is to be read in conjunction with the articles of association and the financial statements of the Company. Copies thereof can be downloaded from the Issuer's site http://www.cytos.com/uploads/Articles_of_Association.pdf and http://www.cytos.com/reports-and-presentations, respectively, and are available free of charge at Cytos Biotechnology Ltd., Wagistrasse 25, 8952 Schlieren, by telephone (number +41 44 733 47 47) during regular business hours, facsimile (number +41 733 47 40) or e-mail (harry.welten@cytos.com).</p> <p>Any investment in the shares of the Company is highly speculative, involves a high degree of risk and should be considered only by investors who are prepared to bear the economic risks of such investment and are able to withstand a total loss of their investment. See "Risk Factors" beginning on page 10 of the Prospectus. For a description of certain restrictions regarding the exercise of the Rights for, and the offering and sale of, the Offered Shares, see "Selling and Transfer Restrictions" beginning on page 63 of the Prospectus.</p>
--	---

This Listing Notice does not constitute an issuing prospectus as defined in Art. 652a and 1156 of the Swiss Code of Obligations.